Amgen Presents New Data For IMDELLTRA In Small Cell Lung Cancer At WCLC 2024; DeLLphi-303 Study Results Show Potential For IMDELLTRA In Combination With A PD-L1 Inhibitor As First-Line Maintenance Therapy In ES-SCLC
Portfolio Pulse from Benzinga Newsdesk
Amgen presented new data at the 2024 World Conference on Lung Cancer, highlighting the potential of IMDELLTRA in combination with PD-L1 inhibitors as a first-line maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC). The DeLLphi-303 study showed promising results, and long-term data from the DeLLphi-301 study demonstrated sustained safety and efficacy.
September 09, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's presentation of new data for IMDELLTRA at the WCLC 2024 highlights its potential in treating ES-SCLC, which could positively impact the company's stock price. The DeLLphi-303 study results show promise for IMDELLTRA in combination with PD-L1 inhibitors, and long-term data from DeLLphi-301 demonstrate sustained safety and efficacy.
The presentation of promising data for IMDELLTRA at a major conference suggests potential advancements in Amgen's product offerings, which could lead to increased investor interest and a positive impact on the stock price. The combination therapy's potential as a first-line maintenance treatment in ES-SCLC is a significant development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90